151 related articles for article (PubMed ID: 37925946)
21. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients.
Kim GA; Han S; Choi GH; Choi J; Lim YS
Aliment Pharmacol Ther; 2020 Jun; 51(11):1169-1179. PubMed ID: 32291781
[TBL] [Abstract][Full Text] [Related]
22. Correlation between low-level viremia and hepatitis B-related hepatocellular carcinoma and recurrence: a retrospective study.
Sun F; Liu Z; Wang B
BMC Cancer; 2021 Oct; 21(1):1103. PubMed ID: 34649509
[TBL] [Abstract][Full Text] [Related]
23. Entecavir Monotherapy Prevents Hepatitis B Virus Recurrence After Liver Transplant for Chronic Hepatitis B Patients: A Long-Term Retrospective Study.
Liu Y; Ho WI; Deng F; Peng S; Lau WY; Chen H
Transplant Proc; 2021 Jun; 53(5):1700-1706. PubMed ID: 34030872
[TBL] [Abstract][Full Text] [Related]
24. Association of Prophylactic Anti-Hepatitis B Virus Therapy With Improved Long-term Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Therapy.
Jang JW; Yoo SH; Nam HC; Jang BH; Sung Sung PS; Lee W; Kwon JH; Nam SW; Bae SH; Yoon SK; Choi JY
Clin Infect Dis; 2020 Jul; 71(3):546-555. PubMed ID: 31504352
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
[TBL] [Abstract][Full Text] [Related]
26. Antiviral therapy predicts the outcomes following resection of hepatocellular carcinoma in patients negative for HBV DNA: a propensity score matching analysis.
Xu M; Zhou Z; Xu R; Zhang H; Lin N; Zhong Y
World J Surg Oncol; 2019 Mar; 17(1):45. PubMed ID: 30823932
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition.
Zhang X; Zhou Y; Chen C; Fang W; Cai X; Zhang X; Zhao M; Zhang B; Jiang W; Lin Z; Ma Y; Yang Y; Huang Y; Zhao H; Xu R; Hong S; Zhang L
J Immunother Cancer; 2019 Nov; 7(1):322. PubMed ID: 31753012
[TBL] [Abstract][Full Text] [Related]
28. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation.
Hu Z; Zeng H; Hou J; Wang J; Xu L; Zhang Y; Chen M; Zhou Z
Viruses; 2022 Mar; 14(4):. PubMed ID: 35458386
[TBL] [Abstract][Full Text] [Related]
29. HBV reactivation and its effect on survival in HBV-related hepatocarcinoma patients undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors.
Shen J; Wang X; Wang N; Wen S; Yang G; Li L; Fu J; Pan X
Front Cell Infect Microbiol; 2023; 13():1179689. PubMed ID: 37197205
[TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics and survival analysis of patients with hepatocellular carcinoma after hepatitis B virus turning negative.
Li H; Guo WM; Xie Q; Sun X; Wang Q
Adv Clin Exp Med; 2022 Jul; 31(7):731-738. PubMed ID: 35302303
[TBL] [Abstract][Full Text] [Related]
31. Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma.
Li Z; Lei Z; Xia Y; Li J; Wang K; Zhang H; Wan X; Yang T; Zhou W; Wu M; Pawlik TM; Lau WY; Shen F
JAMA Surg; 2018 Oct; 153(10):e182721. PubMed ID: 30073257
[TBL] [Abstract][Full Text] [Related]
32. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis B virus DNA negativity acts as a favorable prognostic factor in hepatocellular carcinoma patients.
Li X; Zhong X; Chen ZH; Xing YF; Wu DH; Chen J; Ma XK; Lin Q; Wen JY; Wei L; Wang TT; Ruan DY; Lin ZX; Wu XY; Dong M
Asian Pac J Cancer Prev; 2014; 15(22):9635-41. PubMed ID: 25520081
[TBL] [Abstract][Full Text] [Related]
34. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load.
Sinn DH; Lee J; Goo J; Kim K; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Yoo BC; Paik SW
Hepatology; 2015 Sep; 62(3):694-701. PubMed ID: 25963803
[TBL] [Abstract][Full Text] [Related]
35. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study.
Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH
J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection.
Megna M; Patruno C; Bongiorno MR; Gambardella A; Guarneri C; Romita P; Raimondo A; Loconsole F; Fabbrocini G
Clin Drug Investig; 2022 Jun; 42(6):525-531. PubMed ID: 35633470
[TBL] [Abstract][Full Text] [Related]
37. What can we learn from hepatitis B virus clinical cohorts?
Lin CL; Tseng TC; Kao JH
Liver Int; 2015 Jan; 35 Suppl 1():91-9. PubMed ID: 25529093
[TBL] [Abstract][Full Text] [Related]
38. Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy.
Chung GE; Kim W; Lee JH; Kim YJ; Yoon JH; Lee JM; Lee JY; Kim SH; Kim D; Lee HS
J Gastroenterol Hepatol; 2011 Nov; 26(11):1638-45. PubMed ID: 22011297
[TBL] [Abstract][Full Text] [Related]
39. Association of Hepatitis B Virus DNA Level and Follow-up Interval With Hepatocellular Carcinoma Recurrence.
Wang W; Tian SL; Wang H; Shao CC; Wang YZ; Li YL
JAMA Netw Open; 2020 Apr; 3(4):e203707. PubMed ID: 32338753
[TBL] [Abstract][Full Text] [Related]
40. Risk of hepatitis B virus reactivation and its effect on survival in advanced hepatocellular carcinoma patients treated with hepatic arterial infusion chemotherapy and lenvatinib plus programmed death receptor-1 inhibitors.
Yang Z; Guan R; Fu Y; Hu D; Zhou Z; Chen M; Zhang Y
Front Cell Infect Microbiol; 2024; 14():1336619. PubMed ID: 38415009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
